Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer-Reference-Cited by-同舟云学术

Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer

Published:2007 Issue:6 Volume:120 Page:1355-1363
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Nakahira Shin,Nakamori Shoji,Tsujie Masanori,Takahashi Yuji,Okami Jiro,Yoshioka Shinichi,Yamasaki Makoto,Marubashi Shigeru,Takemasa Ichiro,Miyamoto Atsushi,Takeda Yutaka,Nagano Hiroaki,Dono Keizo,Umeshita Koji,Sakon Masato,Monden Morito

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference42 articles.

1. Pancreatic cancer

2. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

3. Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial

4. Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine)

5. Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine

Cited by 175 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetionamide) and Gemcitabine;Cancers;2024-07-22

2. An NFATc1/SMAD3/cJUN Complex Restricted to SMAD4-Deficient Pancreatic Cancer Guides Rational Therapies;Gastroenterology;2024-02

3. Glycogen synthase kinase 3β: the nexus of chemoresistance, invasive capacity, and cancer stemness in pancreatic cancer;Cancer Drug Resistance;2024-01-31

4. Molecular biomarkers in pancreatic ductal adenocarcinoma;Biomarkers in Cancer Detection and Monitoring of Therapeutics;2024

5. Potential application of nanotechnology in the treatment and overcoming of pancreatic cancer resistance;Recent Advances in Nanocarriers for Pancreatic Cancer Therapy;2024